VAL — ValiRx Share Price
Last trade - 00:00- £4.57m
- £3.45m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.09 | ||
| Price to Tang. Book | 2.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.3% | ||
| Return on Equity | -68.14% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.
Directors
- Kevin Cox NEC
- Suzanne Dilly CEO (43)
- Gerald Desler CFO
- Kumar Nawani OTH
- Mark Treharne OTH
- Kevin Alexander SEC
- Martin Lampshire NED (60)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- January 26th, 2000
- Public Since
- February 28th, 2000
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 132,348,673
- Address
- Eliot Park Innovation Centre, NUNEATON, CV10 7RH
- Web
- https://www.valirx.com/
- Phone
- +44 2476796496
- Auditors
- Adler Shine LLP
Latest News for VAL
Upcoming Events for VAL
Full Year 2023 ValiRx PLC Earnings Release
Half Year 2024 ValiRx PLC Earnings Release
Similar to VAL
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:23 UTC, shares in ValiRx are trading at 3.45p. This share price information is delayed by 15 minutes.
Shares in ValiRx last closed at 3.45p and the price had moved by -66.34% over the past 365 days. In terms of relative price strength the ValiRx share price has underperformed the FTSE All Share Index by -66.33% over the past year.
The overall consensus recommendation for ValiRx is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
ValiRx does not currently pay a dividend.
ValiRx does not currently pay a dividend.
ValiRx does not currently pay a dividend.
To buy shares in ValiRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3.45p, shares in ValiRx had a market capitalisation of £4.57m.
Here are the trading details for ValiRx:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: VAL
Based on an overall assessment of its quality, value and momentum ValiRx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ValiRx. Over the past six months, its share price has underperformed the FTSE All Share Index by -69.57%.
As of the last closing price of 3.45p, shares in ValiRx were trading -49.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ValiRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 3.45p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ValiRx's management team is headed by:
- Kevin Cox - NEC
- Suzanne Dilly - CEO
- Gerald Desler - CFO
- Kumar Nawani - OTH
- Mark Treharne - OTH
- Kevin Alexander - SEC
- Martin Lampshire - NED